Diacerein
Diacerein structure
|
Common Name | Diacerein | ||
|---|---|---|---|---|
| CAS Number | 13739-02-1 | Molecular Weight | 368.294 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 631.5±55.0 °C at 760 mmHg | |
| Molecular Formula | C19H12O8 | Melting Point | 217-2180C | |
| MSDS | N/A | Flash Point | 231.8±25.0 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
[Diacerein].
Ann. Ital. Med. Int. 1(2) , 172-4, (1986)
|
|
|
[Efficacy of diacerein on the symptoms and radiographic progression of osteoarthritis].
Presse Med. 31(39 Pt 2) , 4S13-5, (2002) SYMPTOMATIC EFFECTS OF DIACEREIN: Data obtained from several clinical trials have demonstrated that relief of joint pain obtained with the interleukin-1 inhibitor diacerein is comparable with that observed with non-steroidal anti-inflammatory drugs (NSAIDS) a... |
|
|
Diacerein as a disease-modulating agent in osteoarthritis.
Curr. Rheumatol. Rep. 3(6) , 479-83, (2001) This paper reviews the most recent clinical and experimental studies on diacerein, both of which are under investigation. Diacerein could be a disease-modulating agent in osteoarthritis because structural benefits have been reported in recent trials. Moreover... |
|
|
Diacerein.
Drugs 53(1) , 98-106; discussion 107-8, (1997) Rhein, the active metabolite of diacerein, inhibits interleukin-1 activity. Consequently, collagenase production in articular cartilage is reduced. Rhein dose-dependently inhibits superoxide anion production, chemotaxis and phagocytic activity of neutrophils,... |
|
|
Clinical pharmacokinetics of diacerein.
Clin. Pharmacokinet. 35(5) , 347-59, (1998) Diacerein is a drug for the treatment of patients with osteoarthritis. This drug is administered orally as 50 mg twice daily. Diacerein is entirely converted into rhein before reaching the systemic circulation. Rhein itself is either eliminated by the renal r... |
|
|
Effects of diacerein on biosynthesis activities of chondrocytes in culture.
Biorheology 37(1-2) , 177-84, (2000) The maintenance of articular cartilage integrity requires a balance between anabolic and catabolic processes which are under the control of chondrocytes. These cells are living in an anaerobic environment and normally do not divide. They are responsible for t... |
|
|
Diacerein for osteoarthritis.
Cochrane Database Syst. Rev. (1) , CD005117, (2006) Osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases. Diacerein acts differently from traditional non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit prostaglandin synthesis, leading to adverse gastrointestinal effects. It has be... |
|
|
In vitro effects of diacerein on NO production by chondrocytes in response to proinflammatory mediators.
Biomed Mater Eng 18(1 Suppl) , S99-104, (2008) Osteoarthritis (OA) is a progressive joint disease which represents a combination of several disorders leading to cartilage degradation. The production of nitric oxide (NO) by iNOS, which is stimulated by proinflammatory mediators, is involved in cartilage ca... |
|
|
[Mechanisms of action of diacerein, the first inhibitor of interleukin-1 in osteoarthritis].
Presse Med. 33(9 Pt 2) , S10-2, (2004) DEGRADATION AND REPAIR: Osteoarthritis generally occurs in a context of an overloaded normal cartilage matrix or normal loading of a vulnerable cartilage matrix. Interleukin-1 appears to be principally indicated in degradation phenomena while transforming gro... |